Markets
In a report released today, Douglas Tsao from H.C. Wainwright maintained a Buy rating on Trevena (TRVN – Research Report), with a price target of $5.00. The company’s shares closed last Thursday at $1.71.
According to TipRanks.com, Tsao is a 5-star analyst with an average return of 16.2% and a 51.8% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Crinetics Pharmaceuticals, and Protagonist Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Trevena with a $5.00 average price target.
Based on Trevena’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $69K and GAAP net loss of $11.87 million. In comparison, last year the company earned revenue of $31K and had a GAAP net loss of $6.45 million.